Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on sustainable enzyme-based solutions, announced on February 9, 2026, continued progress on strategic corporate initiatives, including a planned four-for-one forward stock split and the advancement of its corporate name and trading symbol change to Quantum Genesis AI Corp. The initiatives are designed to better position the company for its next phase of development.
The board of directors has authorized a 4-for-1 forward stock split of issued and outstanding common stock. The forward split is intended to enhance the company’s public market profile by recalibrating its capital structure, facilitating greater flexibility in outstanding share structure, and supporting administrative efficiency. The split will be submitted for processing only after completion of the pending corporate name and trading symbol change.
As previously disclosed, Quantumzyme is in the final stages of changing its name to Quantum Genesis AI Corp., reflecting a strategic focus on enzyme innovation through artificial intelligence, computational modeling, and data-driven research. The company anticipates the name and symbol change will be completed in the near term. Immediately following effectiveness, it intends to submit the forward stock split to the Financial Industry Regulatory Authority (FINRA) for review.
Naveen Kulkarni, President of Quantumzyme, stated, “Our planned corporate rebranding and capital structure initiatives are intended to better align the Company’s public market profile with its long-term strategic direction. Completing the name and symbol change first establishes a clear foundation, and, subject to regulatory review, the proposed forward stock split is designed to support a more efficient and accessible public share structure as we continue executing on our technology and operational roadmap.”
If approved, the forward stock split will increase the number of outstanding shares while proportionally adjusting the per-share trading price. The company believes this action may provide benefits including increased flexibility to support future initiatives. The forward split is not intended to change the company’s overall market capitalization and will not affect proportional ownership interests of existing shareholders, except for minor adjustments from fractional shares.
The company expects to provide additional updates regarding the effectiveness of the corporate name and symbol change, as well as the timing and status of the forward split submission, through subsequent public disclosures. The planned split remains subject to regulatory review and approval, with no assurance regarding timing or completion.
For more information, visit www.quantumzymecorp.com and the company’s profile at www.otcmarkets.com/stock/QTZM.
